Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients age at least 18 years of age, or age of consent in the region.~* Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to Revised International System for Staging Lung Cancer criteria of 2010) or recurrent non-small cell lung cancer (NSCLC).~* Histologically or cytologically confirmed diagnosis of predominately non-squamous NSCLC.~* Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin based on local standard of care, for the treatment of advanced or metastatic non-squamous NSCLC.~Exclusion Criteria:~* Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature.~* Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation that is likely to bleed.~* Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALK translocation positive mutations.~* Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy is allowed if surgical resection for primary disease was performed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab-Pfizer (Type: EXPERIMENTAL): Bevacizumab-Pfizer plus paclitaxel and carboplatin
- Bevacizumab-EU (Type: ACTIVE_COMPARATOR): Bevacizumab-EU plus paclitaxel and carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).